Taken together, these data suggest that, in combination with synergistic antigen targeting activity, LoopCAR-1 has the potential to induce complete elimination of refractory lymphoma, leading to significantly improved in vivo efficacy compared with that of the CD19 CAR-T-cell and clinically active CD19/CD22 CAR-T-cell strategies. This evidence concerns the gene CD19 and lymphoma.